Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors

Chiara Mazzanti, Martha A. Zeiger, Nick Costourous, Christopher Umbricht, William H. Westra, Danelle Smith, Helina Somervell, Generoso Bevilacqua, H. Richard Alexander, Steven K. Libutti

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

DNA microarrays allow quick and complete evaluation of a cell's transcriptional activity. Expression genomics is very powerful in that it can generate expression data for a large number of genes simultaneously across multiple samples. In cancer research, an intriguing application of expression arrays includes assessing the molecular components of the neoplastic process and utilizing the data for cancer classification (Miller LD, et al. Cancer Cell 2002;2:353-61). Classification of human cancers into distinct groups based on their molecular profile rather than their histological appearance may prove to be more relevant to specific cancer diagnoses and cancer treatment regimes. Several attempts to formulate a consensus about classification and treatment of thyroid carcinoma based on standard histopathological analysis have resulted in published guidelines for diagnosis and initial disease management (Sherman SI. Lancet 2003;361:501-11). In the past few decades, no improvement has been made in the differential diagnosis of thyroid tumors by fine needle aspiration biopsy, specifically suspicious or indeterminate thyroid lesions, suggesting that a new approach to this should be explored. Therefore, in this study, we developed a gene expression approach to diagnose benign versus malignant thyroid lesions in 73 patients with thyroid tumors. We successfully built a 10 and 6 gene model able to differentiate benign versus malignant thyroid tumors. Our results support the premise that a molecular classification system for thyroid tumors is possible, and this in turn may provide a more accurate diagnostic tool for the clinician managing patients with suspicious thyroid lesions.

Original languageEnglish (US)
Pages (from-to)2898-2903
Number of pages6
JournalCancer Research
Volume64
Issue number8
DOIs
StatePublished - Apr 15 2004
Externally publishedYes

Fingerprint

Gene Expression Profiling
Thyroid Gland
Neoplasms
Neoplastic Processes
Disease Management
Fine Needle Biopsy
Genomics
Oligonucleotide Array Sequence Analysis
Thyroid Neoplasms
Genes
Differential Diagnosis
Guidelines
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mazzanti, C., Zeiger, M. A., Costourous, N., Umbricht, C., Westra, W. H., Smith, D., ... Libutti, S. K. (2004). Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors. Cancer Research, 64(8), 2898-2903. https://doi.org/10.1158/0008-5472.CAN-03-3811

Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors. / Mazzanti, Chiara; Zeiger, Martha A.; Costourous, Nick; Umbricht, Christopher; Westra, William H.; Smith, Danelle; Somervell, Helina; Bevilacqua, Generoso; Alexander, H. Richard; Libutti, Steven K.

In: Cancer Research, Vol. 64, No. 8, 15.04.2004, p. 2898-2903.

Research output: Contribution to journalArticle

Mazzanti, C, Zeiger, MA, Costourous, N, Umbricht, C, Westra, WH, Smith, D, Somervell, H, Bevilacqua, G, Alexander, HR & Libutti, SK 2004, 'Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors', Cancer Research, vol. 64, no. 8, pp. 2898-2903. https://doi.org/10.1158/0008-5472.CAN-03-3811
Mazzanti C, Zeiger MA, Costourous N, Umbricht C, Westra WH, Smith D et al. Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors. Cancer Research. 2004 Apr 15;64(8):2898-2903. https://doi.org/10.1158/0008-5472.CAN-03-3811
Mazzanti, Chiara ; Zeiger, Martha A. ; Costourous, Nick ; Umbricht, Christopher ; Westra, William H. ; Smith, Danelle ; Somervell, Helina ; Bevilacqua, Generoso ; Alexander, H. Richard ; Libutti, Steven K. / Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors. In: Cancer Research. 2004 ; Vol. 64, No. 8. pp. 2898-2903.
@article{39aa570d172040e385bc474312b42632,
title = "Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors",
abstract = "DNA microarrays allow quick and complete evaluation of a cell's transcriptional activity. Expression genomics is very powerful in that it can generate expression data for a large number of genes simultaneously across multiple samples. In cancer research, an intriguing application of expression arrays includes assessing the molecular components of the neoplastic process and utilizing the data for cancer classification (Miller LD, et al. Cancer Cell 2002;2:353-61). Classification of human cancers into distinct groups based on their molecular profile rather than their histological appearance may prove to be more relevant to specific cancer diagnoses and cancer treatment regimes. Several attempts to formulate a consensus about classification and treatment of thyroid carcinoma based on standard histopathological analysis have resulted in published guidelines for diagnosis and initial disease management (Sherman SI. Lancet 2003;361:501-11). In the past few decades, no improvement has been made in the differential diagnosis of thyroid tumors by fine needle aspiration biopsy, specifically suspicious or indeterminate thyroid lesions, suggesting that a new approach to this should be explored. Therefore, in this study, we developed a gene expression approach to diagnose benign versus malignant thyroid lesions in 73 patients with thyroid tumors. We successfully built a 10 and 6 gene model able to differentiate benign versus malignant thyroid tumors. Our results support the premise that a molecular classification system for thyroid tumors is possible, and this in turn may provide a more accurate diagnostic tool for the clinician managing patients with suspicious thyroid lesions.",
author = "Chiara Mazzanti and Zeiger, {Martha A.} and Nick Costourous and Christopher Umbricht and Westra, {William H.} and Danelle Smith and Helina Somervell and Generoso Bevilacqua and Alexander, {H. Richard} and Libutti, {Steven K.}",
year = "2004",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-03-3811",
language = "English (US)",
volume = "64",
pages = "2898--2903",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors

AU - Mazzanti, Chiara

AU - Zeiger, Martha A.

AU - Costourous, Nick

AU - Umbricht, Christopher

AU - Westra, William H.

AU - Smith, Danelle

AU - Somervell, Helina

AU - Bevilacqua, Generoso

AU - Alexander, H. Richard

AU - Libutti, Steven K.

PY - 2004/4/15

Y1 - 2004/4/15

N2 - DNA microarrays allow quick and complete evaluation of a cell's transcriptional activity. Expression genomics is very powerful in that it can generate expression data for a large number of genes simultaneously across multiple samples. In cancer research, an intriguing application of expression arrays includes assessing the molecular components of the neoplastic process and utilizing the data for cancer classification (Miller LD, et al. Cancer Cell 2002;2:353-61). Classification of human cancers into distinct groups based on their molecular profile rather than their histological appearance may prove to be more relevant to specific cancer diagnoses and cancer treatment regimes. Several attempts to formulate a consensus about classification and treatment of thyroid carcinoma based on standard histopathological analysis have resulted in published guidelines for diagnosis and initial disease management (Sherman SI. Lancet 2003;361:501-11). In the past few decades, no improvement has been made in the differential diagnosis of thyroid tumors by fine needle aspiration biopsy, specifically suspicious or indeterminate thyroid lesions, suggesting that a new approach to this should be explored. Therefore, in this study, we developed a gene expression approach to diagnose benign versus malignant thyroid lesions in 73 patients with thyroid tumors. We successfully built a 10 and 6 gene model able to differentiate benign versus malignant thyroid tumors. Our results support the premise that a molecular classification system for thyroid tumors is possible, and this in turn may provide a more accurate diagnostic tool for the clinician managing patients with suspicious thyroid lesions.

AB - DNA microarrays allow quick and complete evaluation of a cell's transcriptional activity. Expression genomics is very powerful in that it can generate expression data for a large number of genes simultaneously across multiple samples. In cancer research, an intriguing application of expression arrays includes assessing the molecular components of the neoplastic process and utilizing the data for cancer classification (Miller LD, et al. Cancer Cell 2002;2:353-61). Classification of human cancers into distinct groups based on their molecular profile rather than their histological appearance may prove to be more relevant to specific cancer diagnoses and cancer treatment regimes. Several attempts to formulate a consensus about classification and treatment of thyroid carcinoma based on standard histopathological analysis have resulted in published guidelines for diagnosis and initial disease management (Sherman SI. Lancet 2003;361:501-11). In the past few decades, no improvement has been made in the differential diagnosis of thyroid tumors by fine needle aspiration biopsy, specifically suspicious or indeterminate thyroid lesions, suggesting that a new approach to this should be explored. Therefore, in this study, we developed a gene expression approach to diagnose benign versus malignant thyroid lesions in 73 patients with thyroid tumors. We successfully built a 10 and 6 gene model able to differentiate benign versus malignant thyroid tumors. Our results support the premise that a molecular classification system for thyroid tumors is possible, and this in turn may provide a more accurate diagnostic tool for the clinician managing patients with suspicious thyroid lesions.

UR - http://www.scopus.com/inward/record.url?scp=9944228652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9944228652&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3811

DO - 10.1158/0008-5472.CAN-03-3811

M3 - Article

C2 - 15087409

AN - SCOPUS:9944228652

VL - 64

SP - 2898

EP - 2903

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -